26.07.2010NovImmune enters exclusive antibody licensing agreement with GenentechYou are hereNewsNovImmune enters exclusive antibody licensing agreement with Genentech
Plan-Les-Ouates/Switzerland– 26th July 2010 - NovImmune, an antibody-focused research and development biotech company, announced today that it successfully entered into an exclusive licensing agreement with Genentech Inc. a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for a proprietary anti-IL-17 fully human monoclonal antibody, and access to back-up antibodies. Recently, the IL-17 signaling pathway has received significant academic and corporate interest as its manipulation may potentially provide new treatment opportunities for major medical conditions.
The anti-IL-17 antibody was generated by NovImmune’s research team and is currently in late preclinical development. Under the terms of the agreement NovImmune will receive an upfront payment and is eligible to receive clinical milestones and royalties on sales. Full financial terms have not been disclosed.
Jack Barbut, CEO, commented “We believe Genentech is the right partner for NovImmune for this program. Genentech brings an in-depth understanding of IL-17 biology and extensive experience in its ability to potentially identify patient populations that may benefit from such a compound thus maximizing chances of successful development.”
James Sabry, Vice President of Genentech Partnering, said “Genentech is very pleased to have the opportunity to work with NovImmune on the development and potential commercialization of this anti-IL-17 antibody. We are hopeful that it has the potential to benefit patients across a range of autoimmune diseases.”
NovImmune SA (‘NovImmune’) is a drug discovery and development company with a focus on therapeutic mAbs for inflammatory diseases and immune-related disorders.
NovImmune has generated, to date, seven proprietary mAbs. The pipeline is a balance of preclinical and clinical compounds, with a mix of both clinically validated as well as novel targets. Each of these portfolio products has the potential to become a medicine for multiple medical conditions due to the overlapping mechanism of action under laying these types of diseases.
Three compounds are at this time in clinical development, with the most advanced in Phase II. The company has currently 70 employees based in Plan-les-Ouates/Geneva, Switzerland.
For more information please visit our website: www.novimmune.com.
Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
For further information please contact:
Director, Business Development and Communication
14, ch. des Aulx
T +41 22 593 51 15
F +41 22 839 71 42
14, ch. des Aulx
T +41 22 839 71 41
F +41 22 839 71 42
BioAlps World Visibitlity Package 201918.03.2019A yearly international programme for our affiliated companies to increase their visibility.
"Bristol-Myers Squibb to Acquire Celgene for About Billion""The combined company will have nine products with more than billion in annual sales"
Anecova SAMedical technology, Devices"Anecova is a life science company focused on the development and commercialization of new technologie in the field of Assisted Reproductive Technologies (ART).
Our goal is to improve the overall quality of care in ART by enabling the use of more physiologic and natural processes.
The first Anecova product aims to restore the fertilization and early development of the embryo to the natural environment of the maternal womb. This technology enables the embryos to start their life in close communication with the maternal environment. This is expected to increase the number of high-quality embryos and improve the success rate of the assisted reproductive cycle."